NEW YORK, Jan. 10, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AstraZeneca investors who were adversely affected by alleged securities fraud between February 23, 2022 and December 17, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/astrazeneca-plc-lawsuit ...

Growth Stocks Overview - Many growth stocks are trading at high valuations, suggesting limited near-term upside potential [1] - Long-term investors may consider rebalancing portfolios by selling recent high performers and buying cheaper growth stocks for better long-term gains [1] AstraZeneca (AZN) - Leading healthcare company investing in next-generation oncology therapies that are more targeted than traditional chemotherapy or radiation [3] - Acquired Fusion Pharmaceuticals, a clinical-stage company developing radioconjugates for precise cancer treatment [4] - Revenue target of $80 billion by 2030, up from $51 billion over the past four quarters [4] - Stock fell 3% last year, trading at a forward P/E of 14, significantly lower than the healthcare sector average of 20 [5] - Potential to be one of the best healthcare stocks over the next five-plus years if growth targets are met [5] Uber Technologies (UBER) - Ride-hailing company with shares down 2% last year due to overblown concerns about competition from Alphabet's Waymo [6] - Remains a dominant and practical option for consumers with strong growth and surging profits [7] - Revenue increased 17% to over $32 billion in the first nine months of 2024, with operating profit jumping from $458 million to over $2 billion year-over-year [7] - Attractive valuation with a forward P/E of 25 and a PEG ratio of around 0.70, supported by improving fundamentals and strong growth prospects [8] Zoom Communications (ZM) - Videoconferencing company still growing despite being perceived as a pandemic play [9] - Zoom's ease of use and flexibility make it a preferred choice over Microsoft Teams, even for organizations with Microsoft 365 subscriptions [10] - Revenue grew 3% year-over-year to $3.5 billion in the nine months ending Oct 31, with a low monthly churn rate of 2.7% [11] - Expanding product offerings with AI features and solutions like Zoom Mail, supporting long-term growth [11] - Stock trades at a modest forward P/E of 15, making it an attractive growth stock to buy and hold [12]

NEW YORK, Jan. 9, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN).Shareholders who purchased shares of AZN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/astrazeneca-plc-loss-submission-form-2/?id=121486&from=4CLASS PERIOD: February 23, 2022 to D ...

In the latest trading session, Astrazeneca (AZN) closed at $66.58, marking a -0.09% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.16%. Elsewhere, the Dow saw an upswing of 0.25%, while the tech-heavy Nasdaq depreciated by 0.06%.The the stock of pharmaceutical has fallen by 0.8% in the past month, leading the Medical sector's loss of 5.77% and the S&P 500's loss of 2.8%.Investors will be eagerly watching for the performance of Astrazeneca in its upcoming earning ...

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and ...

NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN). Shareholders who purchased shares of AZN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/astrazeneca-plc-loss-submission-form-2/?id=120892&from=3  CLASS PERIOD: February 23, ...

Johnson & Johnson on Tuesday said its lung cancer regimen keeps people alive for at least a year longer than AstraZeneca's Tagrisso, the go-to drug for a certain type of lung cancer.J&J in a statement said its drugs – Rybrevant and Lazcluze – showed a statistically significant and clinically meaningful improvement to survival relative to Tagrisso in a pivotal trial. The company expects the benefit to be at least a year and possibly longer, J&J executives said in an interview. The company plans to present th ...

NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AstraZeneca investors who were adversely affected by alleged securities fraud between February 23, 2022 and December 17, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/astrazeneca-plc-lawsuit- ...

NEW YORK, Jan. 6, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, both dates inclusive (the "Class Period"), of the February 21, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.So what: If you purchased AstraZeneca securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or c ...

SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- Robbins LLP informs investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca PLC (NASDAQ: AZN) securities between February 23, 2022 and December 17, 2024. AstraZeneca describes itself as "a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and Biopharmaceuticals, including Cardiovascul ...